| Study Number |
Title |
| 14492B |
Molecular Determinants of Malignancy in Pancreatic Cystic Neoplasms
|
| 09-277-B |
A genotype-guided phase I study of irinotecan administered in combination with 5-fluorouracil/leucovorin (FOLFIRI) and bevacizumab in advanced colorectal cancer patients
|
| 11-0027 |
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy (V212-011)
|
| 12-0112 |
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumour resistant to imatinib
|
| 11-0719 |
AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0980 ADMINISTERED ONCE DAILY IN PATIENTS WITH REFRACTORY SOLID TUMORS OR NON-HODGKIN�S LYMPHOMA
|
| 12-0033 |
A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies
|
| 12-0152 |
A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4
|
| 12-2126 |
Phase II randomized trial of MEK inhibitor MSC1936369B or placebo combined with gemcitabine in metastatic pancreas cancer subjects
|
| 12-1836 |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
|
| 12-1961 |
S1115: Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy
|
Bone